Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.

Estrogen receptor (ER)-alpha and ER-beta function as transcription factors, and both interact with nuclear regulatory proteins to enhance or inhibit transcription. We hypothesized that coregulators are expressed in breast cancer and may be differentially recruited by ERs in the presence of estrogen and tamoxifen. ER-beta was found to be expressed more frequently in node-negative patients (P < 0.05). Expression of steroid receptor coactivator-1 (SRC-1) was associated with nodal positivity (P < 0.05) and resistance to endocrine treatment (P < 0.001). The spatial coexpression of ER-alpha, ER-beta, and the coregulatory proteins was established using immunofluorescence. In both cell lines (MCF-7 and T47D) and in primary breast cancer cell cultures, beta-estradiol up-regulated ER-beta and coregulator protein expression and increased ER-alpha/ER-beta interaction with the estrogen response element (ERE). 4- Hydroxy-tamoxifen (4-OHT) increased ER-alpha and silencing mediator for retinoid and thyroid receptors (SMRT) expression and increased ER-ERE binding. SRC-1 and SMRT were identified at the ER-ERE complex, and interactions between ER isoforms and coregulatory proteins were determined using immunoprecipitation. Both ER-alpha and ER-beta preferentially bound SRC-1 in the presence of beta-estradiol. Conversely, in cells treated with 4-OHT, ER-alpha and ER-beta bound SMRT. Differential recruitment of SRC-1 and SMRT by ER-alpha and ER-beta in the presence of beta-estradiol and 4-OHT may be central to the response of the tumor to endocrine treatment.

[1]  A. Green,et al.  Short-term primary culture of epithelial cells derived from human breast tumours. , 1998, British Journal of Cancer.

[2]  A. Wellstein,et al.  A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells , 2002, Oncogene.

[3]  Simak Ali,et al.  Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α* , 1997, The Journal of Biological Chemistry.

[4]  Neil J McKenna,et al.  Hierarchical Affinities and a Bipartite Interaction Model for Estrogen Receptor Isoforms and Full-length Steroid Receptor Coactivator (SRC/p160) Family Members* , 2003, The Journal of Biological Chemistry.

[5]  C. Klinge,et al.  Selectivity of antibodies to estrogen receptors α and β (ERα and ERβ) for detecting DNA-bound ERα and ERβ in vitro , 2000, Steroids.

[6]  K. Horwitz,et al.  Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer , 2000, Steroids.

[7]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  K. Horwitz,et al.  Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  J. Lakins,et al.  Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. , 2000, Oncology reports.

[10]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Duffy,et al.  Studies on oestrogen receptor-a and -b mRNA in breast cancer , 2001 .

[12]  Neil J McKenna,et al.  From ligand to response: generating diversity in nuclear receptor coregulator function , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  K. Horwitz,et al.  Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  W. McGuire,et al.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen , 2004, Breast Cancer Research and Treatment.

[15]  Baljit Singh,et al.  Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.

[16]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[17]  L. Murphy,et al.  Altered expression of estrogen receptor coregulators during human breast tumorigenesis. , 2000, Cancer research.

[18]  P. Meltzer,et al.  Association of steroid receptor coactivator AIB1 with estrogen receptor-α in breast cancer cells , 2001, Breast Cancer Research and Treatment.

[19]  Y. Niu,et al.  Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer , 2002, British Journal of Cancer.

[20]  J. Kurebayashi,et al.  Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .

[21]  S. Misiti,et al.  Expression and Hormonal Regulation of Coactivator and Corepressor Genes. , 1998, Endocrinology.

[22]  Christof Koch,et al.  Cortical areas in visual awareness , 1995, Nature.

[23]  Donald P. McDonnell,et al.  Connections and Regulation of the Human Estrogen Receptor , 2002, Science.

[24]  V. Cavaillès,et al.  Estrogen receptor cofactors expression in breast and endometrial human cancer cells , 1999, Molecular and Cellular Endocrinology.

[25]  C. Glass,et al.  Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.

[26]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[27]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Decaprio,et al.  Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Kong,et al.  Dynamic inhibition of nuclear receptor activation by corepressor binding. , 2003, Molecular endocrinology.

[30]  V. Speirs,et al.  Immunohistochemical detection of ERβ in breast cancer: towards more detailed receptor profiling? , 2001, British Journal of Cancer.

[31]  M. Davis,et al.  Ligand structure influences autologous downregulation of estrogen receptor–alpha messenger RNA , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  C. Allis,et al.  Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.